Trials / Completed
CompletedNCT00844714
Cardiovascular Risk Markers in Patients With Rheumatoid Arthritis: Effect of Rituximab Therapy
- Status
- Completed
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 20 (actual)
- Sponsor
- University of California, San Francisco · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this investigation is to determine the effects of Rituxan therapy in individuals with rheumatoid arthritis on endothelial function and other markers of endothelial function
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Rituxan | 1000mg rituxan by intravenous infusion will be given on day 1 and day 15 of the study |
Timeline
- Start date
- 2009-11-01
- Primary completion
- 2012-12-01
- Completion
- 2014-12-01
- First posted
- 2009-02-16
- Last updated
- 2015-06-26
- Results posted
- 2014-06-23
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT00844714. Inclusion in this directory is not an endorsement.